Michael Gelband’s Immuneering IMRX Stock Holding History

Michael Gelband’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,516,833	Closed	-$10.6M	–	1775
2025 Q3	$10.6M	Buy	+1,516,833	New	+$7.87M	0.11%	188
2024 Q1	–	Sell	-26,410	Closed	-$194K	–	1704
2023 Q4	$194K	Sell	26,410 -94,393	-78%	-$629K	﹤0.01%	1287
2023 Q3	$928K	Sell	120,803 -6,916	-5%	-$63.6K	0.01%	987
2023 Q2	$1.29M	Buy	127,719 +41,422	+48%	+$398K	0.01%	997
2023 Q1	$838K	Buy	+86,297	New	+$490K	0.01%	1197

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's IMRX Position: Q4 2025 in Review

Michael Gelband sold out of Immuneering (IMRX) in Q4 2025, closing a stake of 1,516,833 shares — an estimated $10.6M sold.

Michael Gelband first reported a position in IMRX in Q1 2023 and held it in 5 quarters. The position peaked at $10.6M in Q3 2025. 86 funds tracked by Wall St. Rank hold IMRX as of Q4 2025.

Michael Gelband reported no remaining Immuneering position as of Q4 2025 after selling out during the quarter.
Michael Gelband sold 1,516,833 Immuneering shares in Q4 2025, an estimated $10.6M.
Michael Gelband first reported a position in Immuneering in Q1 2023 and held it in 5 quarters.
Michael Gelband's Immuneering position peaked at $10.6M in Q3 2025.
86 funds tracked by Wall St. Rank held Immuneering as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.